| Mr Ranjit S Dhaliwal, MD | |
|
3520 Walton Way Ext, Augusta, GA 30909-6605 | |
| (706) 481-9191 | |
| (706) 481-9197 |
| Full Name | Mr Ranjit S Dhaliwal |
|---|---|
| Gender | Male |
| Speciality | Ophthalmology |
| Experience | 41 Years |
| Location | 3520 Walton Way Ext, Augusta, Georgia |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1851387245 | NPI | - | NPPES |
| 00616943F | Medicaid | GA | |
| G38466 | Medicaid | SC |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207W00000X | Ophthalmology | 038466 (Georgia) | Secondary |
| 207WX0107X | Ophthalmology - Retina Specialist | 038466 (Georgia) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Doctors Hospital | Augusta, GA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Palmetto Retina Center Llc | 4486741980 | 11 |
| Retina Consultants Pc | 6608767272 | 3 |
| Palmetto Retina Center Llc | 4486741980 | 11 |
| Retina Consultants Pc | 6608767272 | 3 |
News Archive
Research on the mortality of released prisoners is sparse and what research has been conducted has mainly focused on drug-related causes of death. This is a systematic review to investigate the risk of suicide in recently released prisoners.
After being found not guilty by reason of insanity, it's not typically a crime - rather declining mental health or breaking rules of conditional release like not drinking alcohol - that puts people back in a psychiatric hospital or even jail, researchers say.
Over 90% of malign tumors in the head and neck are originated from carcinomas of squamous cells that appear in superficial areas of the oral cavity. Their detection with salivary biomarkers can contribute to their early treatment, before they transform into tumors.
Linda Watkins, Ph.D., Distinguished Professor, Department of Psychology & Neuroscience and Center for Neuroscience, University of Colorado, Co-Chair, Advisory Board, Xalud Therapeutics, Inc. will present research on activating Glial Cells as part of the speaking faculty at the 7th Annual Pain Therapeutics Summit East in Boston, MA.
Onyx Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval of Kyprolis (carfilzomib) for Injection, a proteasome inhibitor, indicated for the treatment of patients with multiple myeloma who have received at least two prior therapies, including bortezomib and an immunomodulatory agent, and have demonstrated disease progression on or within 60 days of completion of the last therapy.
› Verified 4 days ago
| Entity Name | Retina Consultants Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1750445425 PECOS PAC ID: 6608767272 Enrollment ID: O20040407001249 |
News Archive
Research on the mortality of released prisoners is sparse and what research has been conducted has mainly focused on drug-related causes of death. This is a systematic review to investigate the risk of suicide in recently released prisoners.
After being found not guilty by reason of insanity, it's not typically a crime - rather declining mental health or breaking rules of conditional release like not drinking alcohol - that puts people back in a psychiatric hospital or even jail, researchers say.
Over 90% of malign tumors in the head and neck are originated from carcinomas of squamous cells that appear in superficial areas of the oral cavity. Their detection with salivary biomarkers can contribute to their early treatment, before they transform into tumors.
Linda Watkins, Ph.D., Distinguished Professor, Department of Psychology & Neuroscience and Center for Neuroscience, University of Colorado, Co-Chair, Advisory Board, Xalud Therapeutics, Inc. will present research on activating Glial Cells as part of the speaking faculty at the 7th Annual Pain Therapeutics Summit East in Boston, MA.
Onyx Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval of Kyprolis (carfilzomib) for Injection, a proteasome inhibitor, indicated for the treatment of patients with multiple myeloma who have received at least two prior therapies, including bortezomib and an immunomodulatory agent, and have demonstrated disease progression on or within 60 days of completion of the last therapy.
› Verified 4 days ago
| Entity Name | Palmetto Retina Center Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1255322806 PECOS PAC ID: 4486741980 Enrollment ID: O20071031000150 |
News Archive
Research on the mortality of released prisoners is sparse and what research has been conducted has mainly focused on drug-related causes of death. This is a systematic review to investigate the risk of suicide in recently released prisoners.
After being found not guilty by reason of insanity, it's not typically a crime - rather declining mental health or breaking rules of conditional release like not drinking alcohol - that puts people back in a psychiatric hospital or even jail, researchers say.
Over 90% of malign tumors in the head and neck are originated from carcinomas of squamous cells that appear in superficial areas of the oral cavity. Their detection with salivary biomarkers can contribute to their early treatment, before they transform into tumors.
Linda Watkins, Ph.D., Distinguished Professor, Department of Psychology & Neuroscience and Center for Neuroscience, University of Colorado, Co-Chair, Advisory Board, Xalud Therapeutics, Inc. will present research on activating Glial Cells as part of the speaking faculty at the 7th Annual Pain Therapeutics Summit East in Boston, MA.
Onyx Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval of Kyprolis (carfilzomib) for Injection, a proteasome inhibitor, indicated for the treatment of patients with multiple myeloma who have received at least two prior therapies, including bortezomib and an immunomodulatory agent, and have demonstrated disease progression on or within 60 days of completion of the last therapy.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mr Ranjit S Dhaliwal, MD 3520 Walton Way Ext, Augusta, GA 30909-6605 Ph: (706) 481-9191 | Mr Ranjit S Dhaliwal, MD 3520 Walton Way Ext, Augusta, GA 30909-6605 Ph: (706) 481-9191 |
News Archive
Research on the mortality of released prisoners is sparse and what research has been conducted has mainly focused on drug-related causes of death. This is a systematic review to investigate the risk of suicide in recently released prisoners.
After being found not guilty by reason of insanity, it's not typically a crime - rather declining mental health or breaking rules of conditional release like not drinking alcohol - that puts people back in a psychiatric hospital or even jail, researchers say.
Over 90% of malign tumors in the head and neck are originated from carcinomas of squamous cells that appear in superficial areas of the oral cavity. Their detection with salivary biomarkers can contribute to their early treatment, before they transform into tumors.
Linda Watkins, Ph.D., Distinguished Professor, Department of Psychology & Neuroscience and Center for Neuroscience, University of Colorado, Co-Chair, Advisory Board, Xalud Therapeutics, Inc. will present research on activating Glial Cells as part of the speaking faculty at the 7th Annual Pain Therapeutics Summit East in Boston, MA.
Onyx Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval of Kyprolis (carfilzomib) for Injection, a proteasome inhibitor, indicated for the treatment of patients with multiple myeloma who have received at least two prior therapies, including bortezomib and an immunomodulatory agent, and have demonstrated disease progression on or within 60 days of completion of the last therapy.
› Verified 4 days ago
Dr. Ryan Thomas Smith, MD Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 1330 Interstate Pkwy, Augusta, GA 30909 Phone: 706-651-2020 Fax: 706-855-6674 | |
Amie Elizabeth Squires, MD Ophthalmology Medicare: Not Enrolled in Medicare Practice Location: 1 Freedom Way, Augusta, GA 30904 Phone: 706-733-0188 | |
Dr. Steven E Brooks, MD Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 1120 15th St, Augusta, GA 30912 Phone: 706-721-8623 Fax: 706-721-1459 | |
Dr. Herbert Peter Fechter Iii, MD Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 1330 Interstate Pkwy, Augusta, GA 30909 Phone: 706-651-2020 Fax: 706-855-6674 | |
Zachary Lee Lukowski, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 1120 15th Street, Dept Of Ophthalmology, Augusta, GA 30912 Phone: 706-721-2020 Fax: 706-721-1459 | |
Stephanie L. Goei, MD Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 1120 15th St, Augusta, GA 30912 Phone: 706-721-2020 Fax: 706-721-1156 | |
Dr. Alexander Daniel, Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 1120 15th St, Augusta, GA 30912 Phone: 706-721-7005 |